Island Pharmaceuticals (ASX:ILA) has achieved a major milestone with its lead drug ISLA-101, showing safety and anti-dengue activity in Phase 2a trials, paving the way for therapeutic testing.
A bile tract cancer patient in Imugene’s VAXINIA trial has achieved a remarkable two-year complete response, marking a significant milestone in the fight against advanced cancer.
Argenica Therapeutics advances its stroke treatment with ARG-007, achieving a key safety milestone in its Phase 2 trial, signalling promising potential for brain injury recovery.
ARG-007’s unique mechanism of action and proven safety profile position it as a strong contender in the acute ischaemic stroke treatment landscape.
Tryptamine Therapeutics has successfully completed its Phase 1b trial for TRP-8803, marking a significant step forward in the development of its innovative psilocin-based therapy.